dc.contributor.author | Roberts, Matthew A | |
dc.contributor.author | Darssan, Darsy | |
dc.contributor.author | Badve, Sunil V | |
dc.contributor.author | Carroll, Robert P | |
dc.contributor.author | Fahim, Magid A | |
dc.contributor.author | Haluska, Brian A | |
dc.contributor.author | Hawley, Carmel M | |
dc.contributor.author | Isbel, Nicole M | |
dc.contributor.author | Marshall, Mark R | |
dc.contributor.author | Pascoe, Elaine M | |
dc.contributor.author | Stanton, Tony | |
dc.contributor.author | Tan, Ken-Soon | |
dc.contributor.author | Tonkin, Andrew M | |
dc.contributor.author | Vergara, Liza A | |
dc.contributor.author | et al. | |
dc.date.accessioned | 2023-06-08T00:43:49Z | |
dc.date.available | 2023-06-08T00:43:49Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1420-4096 | en_US |
dc.identifier.doi | 10.1159/000485589 | en_US |
dc.identifier.uri | http://hdl.handle.net/10072/407240 | |
dc.description.abstract | Background/Aims: Cardiac biomarkers are associated with cardiac abnormalities and adverse outcomes in dialysis patients. Our aim was to report the effect of the beta-blocker carvedilol on cardiac biomarkers in adult dialysis patients. Methods: The Beta-Blocker to Lower Cardiovascular Dialysis Events Feasibility Study was a randomized controlled trial comparing carvedilol to placebo. Serum and plasma were collected before the run-in, then 6 and 12 months post-randomization to measure B-type Natriuretic Peptide (BNP), N-terminal BNP (NT-ProBNP), high-sensitivity cardiac troponins I (hs-TnI) and T (hs-TnT), and galectin-3. Left ventricular global longitudinal strain (GLS) was measured by echocardiography at baseline. Results: Seventy-two participants were recruited of whom 49 completed the run-in and were randomized to carvedilol (n=26) or placebo (n=23). Baseline echocardiography demonstrated median (inter-quartile range) GLS of -14.27% (-16.63 to -11.93). NTproBNP and hs-TnT correlated with GLS (Spearman's rho=0.34 [p=0.018] and rho=0.28 [p=0.049], respectively). Median change scores from baseline to 12 months did not differ significantly between participants with complete biomarker data randomized to carvedilol (n=15) or placebo (n=16) for any biomarkers. Conclusions: NT-proBNP and hs-TnT were associated with GLS. However, changes in levels of the biomarkers from baseline to 12 months were not different between groups randomized to carvedilol and placebo. | en_US |
dc.description.peerreviewed | Yes | en_US |
dc.language | English | en_US |
dc.publisher | KARGER | en_US |
dc.relation.ispartofpagefrom | 1033 | en_US |
dc.relation.ispartofpageto | 1044 | en_US |
dc.relation.ispartofissue | 6 | en_US |
dc.relation.ispartofjournal | Kidney and Blood Pressure Research | en_US |
dc.relation.ispartofvolume | 42 | en_US |
dc.subject.fieldofresearch | Clinical sciences | en_US |
dc.subject.fieldofresearchcode | 3202 | en_US |
dc.subject.keywords | Science & Technology | en_US |
dc.subject.keywords | Life Sciences & Biomedicine | en_US |
dc.subject.keywords | Physiology | en_US |
dc.subject.keywords | Urology & Nephrology | en_US |
dc.subject.keywords | Peripheral Vascular Disease | en_US |
dc.title | Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial | en_US |
dc.type | Journal article | en_US |
dc.type.description | C1 - Articles | en_US |
dcterms.bibliographicCitation | Roberts, MA; Darssan, D; Badve, SV; Carroll, RP; Fahim, MA; Haluska, BA; Hawley, CM; Isbel, NM; Marshall, MR; Pascoe, EM; Stanton, T; Tan, K-S; Tonkin, AM; Vergara, LA; et al, Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial, Kidney and Blood Pressure Research, 2017, 42 (6), pp. 1033-1044 | en_US |
dcterms.dateAccepted | 2017-09-03 | |
dcterms.license | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.date.updated | 2021-08-24T04:42:11Z | |
dc.description.version | Version of Record (VoR) | en_US |
gro.rights.copyright | © 2017 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. | en_US |
gro.hasfulltext | Full Text | |
gro.griffith.author | Tan, Ken-Soon | |
gro.griffith.author | Stanton, Tony | |